Healthcare Industry News: BIOLASE
News Release - March 9, 2006
BIOLASE Launches Operations in Australia and New ZealandSAN CLEMENTE, CA--(Healthcare Sales & Marketing Network)--Mar 9, 2006 -- BIOLASE Technology, Inc. (NasdaqNM:BLTI ), a medical technology company that develops, manufactures and markets lasers and related products focused on technologies for improved applications and procedures in dentistry and medicine, announced today the launch of its Australia and New Zealand operations with the establishment of BIOLASE Australia Pty. Ltd. and BIOLASE NZ Limited, which will provide direct sales, service and customer support in these countries. The opening of BIOLASE's Australia and New Zealand offices further establishes the Company's strong presence in the Asia-Pacific region and is driven by its strong customer demand in these markets.
The Company's Australian facility will serve as its Asia-Pacific regional hub. BIOLASE also plans to pursue further market expansion in the Asia-Pacific region over the coming years in China and Japan, both of which represent tremendous growth opportunities. To lead the Asia-Pacific region, including the Company's direct operations in Australia and New Zealand, BIOLASE has appointed Peter Rowland as Vice President and Managing Director. Mr. Rowland is a laser industry veteran with more than 20 years of extensive experience in building direct sales and service operations as well as distribution channel partnerships around the world. Prior to joining BIOLASE, Mr. Rowland held the position of President and CEO of Ellex Medical Pty Ltd, a global manufacturer of ophthalmic laser systems headquartered in Adelaide, Australia.
"As our first direct investment in the Asia-Pacific region, this important step is a major milestone in BIOLASE's global development," commented Robert E. Grant, President and CEO. "The establishment of our new directly owned and managed operations in Australia and New Zealand complement our other international direct operations in Europe and our global headquarters in California. Our new facility and strong sales and service teams across Australia and New Zealand will allow us to provide customers with the full technical, clinical and management resources to support our continuing growth in these key markets."
About BIOLASE Technology, Inc.
BIOLASE Technology, Inc. (http://www.BIOLASE.com) is a medical technology company that develops, manufactures and markets lasers and related products focused on technologies for improved applications and procedures in dentistry and medicine. The Company's products incorporate patented and patent pending technologies focused on reducing pain and improving clinical results. Its primary product, the WaterlaseŽ system, is one of the best selling dental laser systems. The Waterlase system uses a patented combination of water and laser to precisely cut hard tissue, such as bone and teeth, and soft tissue, such as gums, with minimal or no damage to surrounding tissue. The Company also offers the LaserSmile(TM) system, which uses a laser to perform soft tissue and cosmetic procedures, including tooth whitening.
This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current expectations and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein, including, without limitation, the impact of changes in demand for our products, our effectiveness in managing manufacturing costs and expansion of our operations, the impact of technological advances and competition, adoption of our products by dental practitioners, our ability to expand our direct sales force, the timely and effective implementation of strategic alternatives and overall economic and market conditions. Additional information concerning these and other risks are described in the Company's periodic reports it files with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2004 and its quarterly report on Form 10-Q for the quarter ended September 30, 2005. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.
Source: BIOLASE Technology
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.